FGP
IOVA icon

Freestone Grove Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Freestone Grove Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,480
Closed -$51.5K – 758
2025
Q1 		$51.5K Buy
+15,480
New +$79.8K ﹤0.01% 568

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Freestone Grove Partners's IOVA Position: Q2 2025 in Review

Freestone Grove Partners sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 15,480 shares — an estimated $51.5K sold.

Freestone Grove Partners first reported a position in IOVA in Q1 2025 and held it in 1 quarter. The position peaked at $51.5K in Q1 2025. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • Freestone Grove Partners reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 15,480 Iovance Biotherapeutics shares in Q2 2025, an estimated $51.5K.
  • Freestone Grove Partners first reported a position in Iovance Biotherapeutics in Q1 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Iovance Biotherapeutics position peaked at $51.5K in Q1 2025.
  • 255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on Freestone Grove Partners's 13F filing for Q2 2025, filed 14 Aug 2025.